Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HB | P07237 | 1/20 | 0.61 |
| ▸ | PDIA4 | P13667 | 1/20 | 0.61 |
| ▸ | PDIA3 | P30101 | 1/20 | 0.61 |
| ▸ | SLC28A3 | Q9HAS3 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 7/20 | 0.53 |
| ▸ | CA1 | P00915 | 7/20 | 0.53 |
| ▸ | CA9 | Q16790 | 6/20 | 0.53 |
| ▸ | CA2 | P00918 | 6/20 | 0.53 |
| ▸ | CA4 | P22748 | 5/20 | 0.53 |
| ▸ | CA5A | P35218 | 5/20 | 0.53 |
| ▸ | CA7 | P43166 | 5/20 | 0.53 |
| ▸ | CA5B | Q9Y2D0 | 5/20 | 0.53 |
| ▸ | CA6 | P23280 | 4/20 | 0.53 |
| ▸ | CA13 | Q8N1Q1 | 4/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8654501 | 1.00 | P4HB (0.61) | P4HBPDIA4PDIA3SLC28A3TSHR | |
| SCHEMBL8376188 | 0.96 | P4HB (0.57) | P4HBPDIA4PDIA3SLC28A3TSHR | |
| SCHEMBL8376183 | 0.96 | P4HB (0.57) | P4HBPDIA4PDIA3SLC28A3TSHR | |
| SCHEMBL12651491 | 0.91 | P4HB (0.63) | P4HBPDIA4PDIA3TSHRCA12 | |
| SCHEMBL12651482 | 0.91 | P4HB (0.63) | P4HBPDIA4PDIA3TSHRCA12 | |
| SCHEMBL20633976 | 0.90 | P4HB (0.61) | P4HBPDIA4PDIA3TSHRCA12 | |
| SCHEMBL13324379 | 0.89 | P4HB (0.59) | P4HBPDIA4PDIA3TSHRCA12 | |
| SCHEMBL12651802 | 0.87 | P4HB (0.59) | P4HBPDIA4PDIA3TSHRCA12 | |
| SCHEMBL12651652 | 0.87 | P4HB (0.59) | P4HBPDIA4PDIA3TSHRCA12 | |
| SCHEMBL1728397 | 0.85 | P4HB (0.49) | P4HBPDIA4PDIA3SLC28A3TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1609798-B1 | FUSED HETEROCYCLIC DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF | KISSEI PHARMACEUTICAL (JP) | 2012-05-09 | — | — | EP | disclosed |
| EP-1609798-A9 | FUSED HETEROCYCLIC DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2012-01-11 | — | — | EP | disclosed |
| US-7566699-B2 | Fused heterocyclic derivative, medicinal composition containing the same, and medicinal use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2009-07-28 | — | — | US | disclosed |
| US-20060247179-A1 | Fused heterocyclic derivative, medicinal composition containing the same, and medicinal use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2006-11-02 | — | — | US | disclosed |
| EP-1609798-A1 | FUSED HETEROCYCLIC DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2005-12-28 | — | — | EP | disclosed |
| EP-0684254-B1 | Propiophenone derivative and a process for preparing the same | TANABE SEIYAKU CO (JP) | 1999-03-24 | — | — | EP | disclosed |
| EP-0773226-B1 | Propiophenone derivative and processes for preparing the same | TANABE SEIYAKU CO (JP) | 1999-01-13 | — | — | EP | disclosed |
| US-5830873-A | ANTIDIABETIC AGENT | TANABE SEIYAKU CO., LTD. (JP) | 1998-11-03 | — | — | US | disclosed |
| US-5767094-A | Propiophenone derivative and processes for preparing the same | TANABE SEIYAKU CO., LTD. (JP) | 1998-06-16 | — | — | US | disclosed |
| US-5731292-A | ANTIDIABETIC AGENTS | TANABE SEIYAKU CO., LTD. (JP) | 1998-03-24 | — | — | US | disclosed |
| EP-0773226-A1 | Propiophenone derivative and processes for preparing the same | TANABE SEIYAKU CO., LTD. (JP) | 1997-05-14 | — | — | EP | disclosed |
| EP-0684254-A1 | Propiophenone derivative and a process for preparing the same | TANABE SEIYAKU CO., LTD. (JP) | 1995-11-29 | — | — | EP | disclosed |
| US-5424406-A | Useful in treatment of diabetes | TANABE SEIYAKU CO., LTD. (JP) | 1995-06-13 | — | — | US | disclosed |
| EP-0598359-A1 | Hypoglycemic dihydrochalcone derivatives | TANABE SEIYAKU CO., LTD. (JP) | 1994-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247179-A1 | Fused heterocyclic derivative, medicinal composition containing the same, and medicinal use thereof | SLC5A1, SLC5A2, GPR119 | P4HB 661/4885PDIA4 2434/4885PDIA3 1630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.